Fisher Asset Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Fisher Asset Management LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 7.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,560,199 shares of the company’s stock after buying an additional 550,760 shares during the period. Fisher Asset Management LLC’s holdings in Johnson & Johnson were worth $1,225,206,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Daiwa Securities Group Inc. boosted its stake in Johnson & Johnson by 8.0% during the third quarter. Daiwa Securities Group Inc. now owns 384,637 shares of the company’s stock worth $62,335,000 after buying an additional 28,628 shares during the period. Summit Trail Advisors LLC boosted its position in shares of Johnson & Johnson by 15.8% during the third quarter. Summit Trail Advisors LLC now owns 53,162 shares of the company’s stock worth $8,615,000 after buying an additional 7,242 shares during the period. Cahill Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 12.8% in the third quarter. Cahill Financial Advisors Inc. now owns 4,038 shares of the company’s stock valued at $654,000 after buying an additional 459 shares in the last quarter. SevenBridge Financial Group LLC boosted its holdings in Johnson & Johnson by 1.6% during the 3rd quarter. SevenBridge Financial Group LLC now owns 46,218 shares of the company’s stock valued at $7,166,000 after acquiring an additional 727 shares during the period. Finally, Larson Financial Group LLC grew its position in Johnson & Johnson by 24.2% in the 3rd quarter. Larson Financial Group LLC now owns 20,198 shares of the company’s stock valued at $3,273,000 after acquiring an additional 3,932 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Citigroup upped their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.94.

Johnson & Johnson Trading Down 0.2 %

NYSE JNJ opened at $155.17 on Monday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a market capitalization of $373.59 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm’s fifty day moving average price is $160.21 and its 200 day moving average price is $156.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the firm earned $2.66 EPS. The business’s revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.